TheStreet
Your browser is not supported. Please upgrade to one of the following browsers:

Google Chrome

Mozilla Firefox

Apple Safari

Microsoft Internet Explorer 9+

You may proceed to the site by clicking here, however some pages might not work correctly.
ip-192-168-72-119
JOIN JIM CRAMER'S INVESTING CLUB
  • Log In
    Your Account
    Account Preferences Newsletters Alerts
    Logout
  • Newsletters
  • Subscribe
    Access insights and guidance from our Wall Street pros. Find the product that's right for you.
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement Daily
    • Stocks Under $10
    • Top Stocks
    • Trifecta Stocks
    • Real Money Pro Portfolio
    • Chairman's Club
    • Compare All
  • Jim Cramer
    • Action Alerts PLUS
    • Cramer's Blog
    • Cramer's Monthly Call
    • Jim Cramer's Best Stocks
    • Cramer's Articles
    • Mad Money
    • 25 Rules for Investing
    • 10 Commandments
  • Investing
    • Earnings
    • Funds
    • Bitcoin
    • Fixed Income
    • Options
    • Futures
    • Stocks
    • ETFs
  • Personal Finance
    • Credit Cards
    • Debt Management
    • Mortgages
    • Real Estate
    • Taxes
    • Education
    • Savings
    • Insurance
  • Retirement
    • Social Security
    • Estate Planning
    • IRAs
    • 401k
  • Technology
    • Cybersecurity
  • Markets
    • Currencies
    • Rates and Bonds
    • Commodities
    • Emerging Markets
    • Mergers and Acquisitions
    • IPOs
    • Bankruptcy
    • Regulation
    • Corporate Governance
  • How-To
  • Video
TheStreet Ratings

Research Center
Reports
Stock Upgrades & Downgrades

Cleveland BioLabs, Inc.

Find Ratings Reports
CBLI : NASDAQ :
$3.94 | %
Today's Range: 3.81 - 4.04
Avg. Daily Volume: 0
01/22/21 - 4:00 PM ET
Rating Summary Rating Detail Financial Analysis Peer Group

Financial Analysis


CLEVELAND BIOLABS INC's gross profit margin for the third quarter of its fiscal year 2020 has significantly decreased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its subsector. CLEVELAND BIOLABS INC is extremely liquid. Currently, the Quick Ratio is 6.55 which clearly shows the ability to cover any short-term cash needs. CBLI managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.

At the same time, stockholders' equity ("net worth") has greatly increased by 33.83% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q3 FY20 Q3 FY19
Net Sales ($mil)0.040.27
EBITDA ($mil)-0.77-0.52
EBIT ($mil)-0.77-0.52
Net Income ($mil)-0.75-0.45


Balance Sheet Q3 FY20 Q3 FY19
Cash & Equiv. ($mil)3.041.91
Total Assets ($mil)3.232.23
Total Debt ($mil)0.00.0
Equity ($mil)-2.23-3.36


Profitability Q3 FY20 Q3 FY19
Gross Profit Margin-1750.0-191.11
EBITDA Margin-1750.0-191.11
Operating Margin-1756.82-191.85
Sales Turnover0.20.44
Return on Assets-74.62-106.41
Return on Equity0.00.0
Debt Q3 FY20 Q3 FY19
Current Ratio6.663.87
Debt/Capital0.00.0
Interest Expense0.00.0
Interest Coverage0.00.0


Share Data Q3 FY20 Q3 FY19
Shares outstanding (mil)13.0211.3
Div / share0.00.0
EPS-0.06-0.04
Book value / share-0.17-0.3
Institutional Own % n/a n/a
Avg Daily Volume2768689.0207870.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
CBLI NM Peers 33.50   CBLI NM Peers 102.28

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

CBLI's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

CBLI's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
CBLI NA Peers 21.30   CBLI NA Peers 0.70

Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.

Ratio not available.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
CBLI NM Peers 11.72   CBLI 4.77 Peers 5.00

Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

CBLI's P/B is negative making this valuation measure meaningless.

 

Average. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

CBLI is expected to keep pace with its peers on the basis of earnings growth.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
CBLI 75.41 Peers 1929.85   CBLI -35.68 Peers 699.03

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

CBLI is trading at a significant discount to its subsector on this measurement.

 

Lower. A sales growth rate that trails the subsector implies that a company is losing market share.

CBLI significantly trails its peers on the basis of sales growth.

 

 

Latest Stock Upgrades/Downgrades

View more upgrades/downgrades >>
Ratings Guide
  • INVESTING
  • PERSONAL FINANCE
  • RETIREMENT
  • TECHNOLOGY
  • MARKETS
  • HOW-TO
  • Video
  • Opinion
  • Politics
  • Lifestyle

Featured Topics

  • Mad Money
  • Stock Market Today
  • Dow Jones Today
  • Stocks
  • Funds
  • ETFs
  • Bitcoin
  • Travel
  • Sports
  • Health
  • Food and Drink
  • Cybersecurity
  • Penny Stocks
  • How to Invest in Stocks
  • Social Security
  • 401K
  • IRAs
  • Taxes
  • Index Funds
  • Roth IRAs
  • Home Insurance
  • Health Insurance
  • Disability Insurance
  • Prime Day

Popular Pages

  • Best Stocks
  • Best Stocks to Buy
  • Earnings Calendar
  • Ex Dividend Date
  • Mutual Fund Ratings
  • Best Online Brokers
  • Rates and Bonds
  • Commodities
  • Treasury Bonds
  • Junk Bonds
  • Corporate Bonds
  • Municipal Bonds

Subscriptions

  • Action Alerts PLUS
  • Quant Ratings
  • Real Money
  • Real Money Pro
  • Retirement Daily
  • Stocks Under $10
  • Top Stocks
  • Trifecta Stocks
  • RMP Portfolio
  • Chairman's Club

Stay Connected

  • Sitemap
  • Feedback
  • About Us
  • Investor Relations
  • Advertise
  • Reprints
  • Customer Service
  • Employment
  • Privacy Policy
  • Terms of Use
  • Topic Archive
  • Video Sitemap
  • Data
  • Affiliate
  • Press Room
© 1996- TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.

  • INVEST WITH CRAMER FREE for 14 Days→
    • Jim Cramer
      • Action Alerts PLUS
      • Cramer's Blog
      • Cramer's Monthly Call
      • Jim Cramer's Best Stocks
      • Cramer's Articles
      • Mad Money
      • 25 Rules for Investing
      • 10 Commandments
    • Investing
      • Earnings
      • Funds
      • Bitcoin
      • Fixed Income
      • Options
      • Futures
      • Stocks
      • ETFs
    • Personal Finance
      • Credit Cards
      • Debt Management
      • Mortgages
      • Real Estate
      • Taxes
      • Education
      • Savings
      • Insurance
    • Retirement
      • Social Security
      • Estate Planning
      • IRAs
      • 401k
    • Technology
      • Cybersecurity
    • Markets
      • Currencies
      • Rates and Bonds
      • Commodities
      • Emerging Markets
      • Mergers and Acquisitions
      • IPOs
      • Bankruptcy
      • Regulation
      • Corporate Governance
    • How-To
    • Video
    Privacy Policy|Terms of Use
    © 1996-2018 TheStreet Inc. All rights reserved